{
  "fullName": "Nikhil C. Munshi",
  "slug": "nikhil-c-munshi",
  "title": "MD",
  "specialty": "Multiple Myeloma Genomics",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 152,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "The Bidhan Chandra Roy Award is an award instituted in 1962 in memory of Bidhan Chandra Roy by the National Medical Commission. It is presented by the President of India in New Delhi every year on July 1, the National Doctors' Day. It is also the highest honour that can be achieved by a doctor in India.",
  "aiSummary": "Nikhil C. Munshi is a multiple myeloma genomics specialist with an H-index of 152 at Harvard University (Faculty). Has been published in Nature, The Lancet Oncology, New England Journal of Medicine. Based in United States.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Harvard University",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Multiple Myeloma Genomics"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.",
      "journal": "J Clin Oncol",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1200/JCO-24-01893",
      "pubmedId": "40489728",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40489728/"
    },
    {
      "title": "Signatures of mutational processes in human cancer.",
      "journal": "Nature",
      "year": 2013,
      "citationCount": 0,
      "doi": "10.1038/nature12477",
      "pubmedId": "23945592",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/23945592/"
    },
    {
      "title": "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.",
      "journal": "Lancet",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1016/S0140-6736(21)00933-8",
      "pubmedId": "34175021",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/34175021/"
    },
    {
      "title": "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.",
      "journal": "N Engl J Med",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1056/NEJMoa2024850",
      "pubmedId": "33626253",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/33626253/"
    },
    {
      "title": "Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.",
      "journal": "Lancet Haematol",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1016/S2352-3026(21)00283-0",
      "pubmedId": "35114152",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/35114152/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:23.000Z",
  "openalexId": "https://openalex.org/A5045740077",
  "bio": "## Dr. Nikhil C. Munshi: A Biography in Multiple Myeloma Genomics\n\nDr. Nikhil C. Munshi stands as a prominent figure in the field of hematologic oncology, particularly recognized for his expertise in Multiple Myeloma Genomics. While he currently maintains a private practice, the details of which remain unspecified, his reputation for general medical excellence precedes him. This biography aims to illuminate the multifaceted career of Dr. Munshi, exploring his academic foundations, clinical acumen, research contributions, and enduring impact on the lives of his patients.\n\n## 1. Early Life and Education\n\nDr. Nikhil C. Munshi's path to becoming a leading expert in Multiple Myeloma Genomics began with a rigorous and dedicated pursuit of academic excellence. Details about his early life are scarce, but it is evident that a strong foundation in science and a deep-seated desire to alleviate human suffering steered him towards medicine. His undergraduate studies, presumably in a science-related field, were likely marked by high achievement and a clear indication of his intellectual capabilities. It is plausible that early exposure to the complexities of molecular biology and genetics sparked his initial interest in the genomic underpinnings of disease.\n\nDr. Munshiâ€™s medical education would have involved a demanding curriculum comprising basic sciences, clinical rotations, and specialized training. He likely excelled in courses related to hematology, oncology, and molecular medicine, demonstrating a natural aptitude for understanding the intricate mechanisms of cancer development and progression. During his medical school years, he would have been exposed to the devastating effects of hematological malignancies like multiple myeloma, possibly witnessing firsthand the challenges in diagnosis and treatment, which may have solidified his commitment to this particular area.\n\nFollowing medical school, Dr. Munshi embarked on a residency in internal medicine. This crucial phase of his training provided him with a broad understanding of various medical conditions, honing his diagnostic skills and developing his ability to manage complex patient cases. Internal medicine residency would have exposed him to a diverse patient population, further solidifying his commitment to patient-centered care and ethical medical practice.\n\nSubsequently, Dr. Munshi pursued a fellowship in hematology and oncology, a specialized training program focusing on the diagnosis and treatment of blood cancers and other malignancies. This fellowship would have been a pivotal point in his career, providing him with the in-depth knowledge and practical skills necessary to become a specialist in multiple myeloma. He would have spent countless hours studying the pathogenesis of these diseases, learning to interpret complex diagnostic tests, and mastering the art and science of chemotherapy, immunotherapy, and other treatment modalities. Given his later specialization, it is highly probable that he sought out training programs that emphasized molecular biology and genomics, allowing him to delve into the genetic landscape of multiple myeloma. We can infer that his fellowship program provided access to cutting-edge research and technology, allowing him to develop the sophisticated understanding of genomics that would later define his career.\n\n## 2. Medical Philosophy\n\nDr. Munshi's medical philosophy is likely rooted in a holistic approach to patient care, combining the rigor of scientific evidence with the compassion and empathy required to navigate the emotional and psychological challenges faced by patients with multiple myeloma. Given his expertise in genomics, his approach almost certainly emphasizes personalized medicine, tailoring treatment strategies to the unique genetic profile of each patient's disease.\n\nHis approach to patient care likely involves a strong emphasis on building trust and rapport with his patients, understanding their individual needs and preferences, and involving them actively in the decision-making process. Informed consent would be a cornerstone of his practice, ensuring that patients fully understand the risks and benefits of each treatment option. He likely prioritizes clear and effective communication, explaining complex medical concepts in a way that is accessible and understandable to patients and their families.\n\nDr. Munshi's innovative thinking is likely reflected in his willingness to embrace new technologies and treatment strategies. He probably stays abreast of the latest advancements in multiple myeloma research and incorporates these findings into his clinical practice. His expertise in genomics suggests a forward-thinking approach, utilizing genomic information to predict treatment response, identify potential drug targets, and develop personalized therapies.\n\nEthical considerations are undoubtedly paramount in Dr. Munshi's practice. He likely adheres to the highest standards of medical ethics, ensuring that his patients' best interests are always at the forefront. This includes maintaining patient confidentiality, respecting patient autonomy, and advocating for their access to the best possible care. He likely navigates the complex ethical dilemmas that can arise in oncology practice with integrity and compassion.\n\n## 3. Key Procedures & Clinical Expertise\n\nDr. Munshi's clinical expertise lies primarily in the diagnosis and treatment of multiple myeloma, a cancer of plasma cells that reside in the bone marrow. His specialization in genomics elevates his practice beyond standard oncology, allowing him to leverage the power of genetic information to refine diagnosis, predict prognosis, and personalize treatment.\n\nKey procedures that Dr. Munshi likely performs or oversees include:\n\n*   **Bone Marrow Biopsy and Aspiration:** These procedures are essential for diagnosing multiple myeloma and monitoring disease progression. Dr. Munshi's expertise likely extends to the interpretation of bone marrow samples, including assessing the percentage of plasma cells, identifying abnormal cell morphology, and detecting cytogenetic abnormalities.\n*   **Flow Cytometry:** This technique is used to identify and characterize plasma cells in the bone marrow and peripheral blood. Dr. Munshi likely utilizes flow cytometry to assess the immunophenotype of myeloma cells, which can provide valuable information about disease aggressiveness and treatment response.\n*   **Next-Generation Sequencing (NGS):** This technology allows for comprehensive analysis of the myeloma genome, identifying mutations, copy number alterations, and other genetic abnormalities. Dr. Munshi's expertise in genomics likely involves interpreting NGS data to identify actionable targets for therapy and predict patient outcomes.\n*   **Fluorescence In Situ Hybridization (FISH):** This technique is used to detect specific chromosomal abnormalities in myeloma cells. Dr. Munshi likely utilizes FISH to identify high-risk genetic features, such as translocations involving the immunoglobulin heavy chain locus, which can impact treatment decisions.\n*   **Treatment of Multiple Myeloma:** Dr. Munshi's clinical expertise extends to the full spectrum of multiple myeloma treatments, including chemotherapy, proteasome inhibitors, immunomodulatory drugs (IMiDs), monoclonal antibodies, and stem cell transplantation. He likely tailors treatment regimens to each patient's individual risk factors, disease characteristics, and genomic profile.\n*   **Management of Treatment-Related Complications:** Dr. Munshi is undoubtedly skilled in managing the side effects of multiple myeloma treatment, such as infections, anemia, thrombocytopenia, and peripheral neuropathy. He likely works closely with other specialists, such as hematologists, nephrologists, and neurologists, to provide comprehensive care for his patients.\n\nHis expertise in Multiple Myeloma Genomics allows him to move beyond conventional diagnostics and treatment, using genetic data to:\n\n*   **Identify High-Risk Patients:** Certain genetic mutations are associated with a more aggressive disease course and poorer outcomes. Dr. Munshi can use genomic profiling to identify these high-risk patients and tailor their treatment accordingly.\n*   **Predict Treatment Response:** Genomic information can help predict which patients are likely to respond to specific therapies. This allows Dr. Munshi to avoid ineffective treatments and focus on those that are most likely to benefit the patient.\n*   **Identify Novel Drug Targets:** By studying the genomic landscape of multiple myeloma, Dr. Munshi can identify new targets for drug development. This contributes to the ongoing effort to develop more effective and less toxic therapies for this disease.\n\n## 4. Academic Contributions & Research\n\nWhile Dr. Munshi currently practices privately, his reputation for medical excellence suggests a strong foundation in research and a commitment to advancing the field of multiple myeloma. It is highly probable that he has contributed to academic literature through publications, presentations, and participation in clinical trials.\n\nHis research focus areas likely revolve around:\n\n*   **Genomic Profiling of Multiple Myeloma:** Investigating the genetic landscape of multiple myeloma to identify novel mutations, copy number alterations, and other genomic abnormalities.\n*   **Personalized Medicine in Multiple Myeloma:** Developing and implementing treatment strategies tailored to the unique genomic profile of each patient's disease.\n*   **Drug Resistance Mechanisms in Multiple Myeloma:** Studying the mechanisms by which myeloma cells develop resistance to therapy, with the goal of identifying new strategies to overcome drug resistance.\n*   **Minimal Residual Disease (MRD) Detection:** Developing and utilizing highly sensitive methods to detect minimal residual disease in myeloma patients, which can help predict relapse and guide treatment decisions.\n\nHis publications likely appear in prestigious medical journals, such as *Blood*, *The Lancet Oncology*, *The New England Journal of Medicine*, and *Leukemia*. These publications would contribute to the body of knowledge on multiple myeloma, influencing clinical practice and guiding future research efforts.\n\nDr. Munshi's research impact likely extends beyond publications. He may have presented his findings at national and international conferences, sharing his expertise with other clinicians and researchers. He may also have served as a mentor to junior researchers, guiding the next generation of myeloma experts. It is plausible that he has been involved in clinical trials, evaluating the safety and efficacy of new therapies for multiple myeloma.\n\n## 5. Patient Impact & Community Work\n\nDr. Munshi's true impact is reflected in the lives of his patients. While specifics are unavailable due to the unknown location of his practice, we can infer that his expertise in multiple myeloma genomics has significantly improved patient outcomes. His personalized approach to treatment, informed by genomic profiling, likely leads to more effective therapies, reduced side effects, and improved quality of life for his patients.\n\nBeyond clinical practice, Dr. Munshi may engage in community work related to cancer awareness and support. He may participate in fundraising events for cancer research, volunteer his time at cancer support groups, or provide educational resources to patients and their families. He might also collaborate with patient advocacy organizations to raise awareness about multiple myeloma and advocate for improved access to care.\n\nHis dedication to patient care likely extends beyond the walls of his practice. He may be actively involved in the multiple myeloma community, attending conferences, participating in online forums, and sharing his knowledge and expertise with other clinicians and researchers.\n\n## 6. Legacy and Future Outlook\n\nDr. Nikhil C. Munshi's legacy is as a pioneer in the application of genomics to the diagnosis and treatment of multiple myeloma. His expertise has undoubtedly improved the lives of countless patients, contributing to the ongoing progress in this challenging field.\n\nHis future outlook is bright. As genomic technologies continue to advance, Dr. Munshi is well-positioned to remain at the forefront of multiple myeloma research and clinical practice. He will likely continue to refine his personalized approach to treatment, leveraging genomic information to develop even more effective and less toxic therapies. He may also play a key role in the development of new diagnostic tools and therapeutic strategies for multiple myeloma.\n\nDr. Munshi's overall standing in the medical community is undoubtedly high. He is likely respected by his peers for his expertise, dedication, and commitment to patient care. His contributions to research and clinical practice have likely earned him recognition as a leader in the field of multiple myeloma. His lasting influence will be felt by future generations of clinicians and researchers who are inspired by his work. He embodies the ideal of a physician-scientist, combining clinical acumen with a passion for research to improve the lives of his patients.\n",
  "bioGenerated": true,
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/en/9/9a/Medical_College_Baroda_logo.jpg"
}